As I reflect on this milestone, I am filled with gratitude and a profound sense of accomplishment.

It’s astonishing to think that I am on the verge of releasing my 100th podcast episode. When I embarked on this venture, I aimed to produce 100 episodes, but I never envisioned the depth of impact it would have on both my listeners and myself.

The pandemic brought about unforeseen challenges for businesses and individuals, prompting me to explore ways to aid my community in remaining connected.

This exploration led me to discover the unifying potential of podcasting and newsletters in alleviating feelings of isolation.

Throughout the past few years, I have learned, stumbled, experimented, and continuously refined my podcast. I am immensely thankful to every guest who joined me on this journey and to those whose contributions through donations and sponsorships have allowed me to enhance the show’s budget.

A heartfelt thank you goes out to the listeners for engaging with the podcast—by clicking, downloading, commenting, sharing, and spending time with me.

The success of any show is defined by its audience, and I am delighted and grateful to have created something that provides value to you, the listener. Statistics reveal that the show has reached over 9,000 listeners worldwide, with a significant audience in Europe, 40% in North America, and 10% elsewhere.

I am thrilled to announce that, due to collaborations with Podcastnotes.org and Labiotech.eu, my podcast has now reached over 70,000 thought leaders across the globe.

As I strive to enhance my podcast further, I extend my gratitude to my listeners for their unwavering support.

Your downloads, likes, comments, shares, and follows are pivotal in helping me expand my reach, allowing more individuals to benefit from the content I create.

I am dedicated to promoting scientific entrepreneurs and fostering a bright future for humanity as long as I have funding and as long as my listeners affirm that my show is meaningful.

In celebration of this milestone, I have prepared a special episode to honor my speakers and listeners. I am excited to present the five most downloaded episodes from the last three years.

Thank you for being an integral part of this journey with me.

Number 5: Sascha Bucher — Forty51 Ventures — Episode #34 — February 11, 2021

Are you an entrepreneur trying to make sense of the investment landscape?

Do you wish for a guide to help you navigate the complexities of the market?

Look no further!

In this episode, I chat with Sascha Bucher, a venture capital specialist with over a decade of experience in structuring deals within the pharmaceutical industry.

Having worked at leading venture funds and firms like Roivant Sciences, Roche, and UBS, Sascha has been involved in transactions worth billions. Now, at Forty51 Ventures, he and his team are working to bridge the “Life Science Valley of Death” in Central Europe, equipping life science entrepreneurs with essential resources for success.

However, the journey toward success in drug development is fraught with challenges. It requires thorough research, the ability to transform scientific insights into viable products, and the expertise to successfully market them.

Furthermore, as deal structuring is a B2B endeavor, entrepreneurs must learn to negotiate with the pharmaceutical sector and secure multi-billion dollar contracts.

In this engaging conversation, Sascha shares his insider tips on building relationships with business development, research and development, and C-suite executives, becoming a trusted collaborator. Don’t miss this opportunity to gather valuable insights into the daily life of a venture capitalist and learn how to excel in the competitive realm of drug development.

Number 4: Ana Trbovich — Episode #37 — March 7, 2021

In this essential podcast episode, we delve into the innovative applications of blockchain technology in the energy sector with Ana Trbovich, co-founder and COO of Grid Singularity, and Vice-Chair of the Energy Web Foundation.

Ana brings a wealth of entrepreneurial experience and insights, particularly from her time in the tech hub of Berlin, illustrating how blockchain is transforming the energy industry beyond its traditional role as a payment system.

Her expertise extends further, as she serves on the UNECE Carbon Neutrality and DENA SET Hub Advisory Boards, and holds independent board positions at organizations like the European Institute for Innovation and Technology (EIT), Axa, and the Belgrade Philharmonic.

Ana also teaches Entrepreneurship at FEFA, a prestigious business school in Belgrade, Serbia, where she was Dean from 2012 to 2015. Her diverse background also includes consulting for international bodies like the EU and the World Bank on governance, competitiveness, and innovation policy.

Don’t miss this chance to learn from a true pioneer in blockchain and energy.

Number 3: Jonathan Sporn — Episode 79 — June 28, 2022

As the global mental health crisis continues to impact roughly one billion individuals, many experts argue this number might be an underrepresentation.

In this episode, Dr. Jonathan Sporn, CEO of Gilgamesh Pharmaceutical, discusses the pressing medical needs in mental health and the exciting potential of new psychedelic drug development.

Dr. Sporn, a board-certified psychiatrist and assistant professor at Columbia University, shares his perspectives on the history of psychedelic drug innovation, the investors in this field, and the fundamental elements required to build a successful and innovative drug development enterprise.

He also explores the efficacy of psychedelic drugs for mental health treatment, the role of artificial intelligence in this space, and the investment climate in the U.S. regarding new innovations.

As we continue to confront the mental health crisis, the possibilities for psychedelic drugs to alleviate societal burdens remain a captivating topic.

Tune in to the podcast for deeper insights into this promising field.

Number 2: Heike Schön — Episode 71 — March 28, 2022

Clinical trial failures are all too common in the pharmaceutical landscape, with nearly 90% of product ideas not making it through trials.

While efficacy is often the primary reason for failure, other manageable factors can significantly enhance the likelihood of success. These setbacks can be financially burdensome for sponsors and investors, but addressing controllable failure sources can save both time and money.

In this podcast episode, Heike Schön, Managing Director and Co-Founder of Lumis International and Lumis Consulting, shares her extensive expertise in clinical drug development and trials.

With over 25 years of leadership experience in international clinical research, Heike provides valuable insights into the clinical trial process, regulatory requirements, and techniques for getting trials back on track.

She also discusses the trend between in-house versus outsourced management of clinical studies and shares her predictions for the future of clinical trials.

Tune in to gain knowledge from a leading expert in the field.

Number 1: Alexander Belcredi — Episode #9 — April 1, 2020

It’s difficult to believe that I am nearing episode 100. When I began this journey, I could never have imagined its influence on my listeners and myself.

That’s why I am excited to welcome back Alexander Belcredi, co-founder of Phagomed, to explore how entrepreneurs can achieve unexpected outcomes in business.

His episode, recorded in March 2020, has received the most downloads.

Alexander and his co-CEO, Lorenzo Corsini, founded their company in 2015 with the aim of developing alternatives to antibiotics. In April 2020, they were in the midst of fundraising, and just two years later, they secured an acquisition deal with BioNTech.

In this episode, Alexander discusses Phagomed’s innovative strategy for treating bacterial infections without relying on antibiotics, the hurdles they faced in drug development, and the competitive landscape of the anti-bacterial sector.

He also offers insights into the clinical development process, the necessity of preparation for fundraising, and the significance of European public funds in leveraging private investments.

Tune in to learn more about Phagomed’s groundbreaking approach to treating bacterial infections and how they achieved remarkable success in business.

What the Future Holds for the Podcast

As I look toward 2023, I have set ambitious goals to grow and enhance the podcast. A primary objective is to evolve the podcast into a video format, providing a more effective platform for showcasing the brands and voices of our speakers.

To achieve this, I am actively seeking speakers who can disseminate essential information in the following areas: - Holistic health, preventive medicine, and well-being; - Pharma and health tech; - Artificial intelligence; - Climate change; - Entrepreneurship and investing.

Other goals for 2023 include: - Doubling organic reach on social media, - Establishing more media partnerships, - Increasing cash flows to support social media marketing for partner brands, - Producing an additional 50 episodes featuring engaging speakers to amplify their messages.

Overall, I am eager about the opportunities and challenges that 2023 will present.

I am committed to realizing these goals and making a positive impact on our community.